Pharmaceutical News RSS Feed - Pharmaceutical News

Boehringer Ingelheim announces FDA acceptance of NDA filing for tiotropium and olodaterol FDC

Boehringer Ingelheim announces FDA acceptance of NDA filing for tiotropium and olodaterol FDC

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. [More]
Investigational drug focuses on slowing Alzheimer's disease progression

Investigational drug focuses on slowing Alzheimer's disease progression

Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug that proposes to do just that. [More]
Insulin can protect cells of pancreas from acute pancreatitis

Insulin can protect cells of pancreas from acute pancreatitis

Scientists from The University of Manchester have discovered that insulin can protect the cells of the pancreas from acute pancreatitis - a disease for which there is currently no treatment. [More]
Cognitive therapy combined with antidepressant drug effective for severe nonchronic depression

Cognitive therapy combined with antidepressant drug effective for severe nonchronic depression

The odds that a person who suffers from severe, nonchronic depression will recover are improved by as much as 30 percent if they are treated with a combination of cognitive therapy and antidepressant medicine rather than by antidepressants alone. [More]

Painkillers may not offer relief to people suffering from irritable bowel syndrome

University of Adelaide researchers have discovered that the immune system is defective in people suffering from irritable bowel syndrome, which is a major reason why sufferers have ongoing issues with pain. [More]
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]
Shuganjieyu capsule effectively reverses depressive by increasing neurotrophic factor

Shuganjieyu capsule effectively reverses depressive by increasing neurotrophic factor

Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Administration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. [More]
Researchers focus on how exposure to opioids may alter expression of OPRM1 gene

Researchers focus on how exposure to opioids may alter expression of OPRM1 gene

Some infants born with neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure have a more difficult time going through withdrawal than others, but the underlying reasons are not well understood. [More]
Studies support clinical use of antidepressants for treatment of postoperative pain

Studies support clinical use of antidepressants for treatment of postoperative pain

Antidepressants are known to provide effective pain relief for various chronic pain conditions; however, the jury is still out on their use in treating the millions of patients who suffer from acute or chronic pain following surgery. [More]

Perampanel does not offer added benefit for patients with Epilepsy

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). [More]
New therapeutic drug may prevent respiratory depression in patients taking opioid medication

New therapeutic drug may prevent respiratory depression in patients taking opioid medication

People taking prescription opioids to treat moderate to severe pain may be able to breathe a little easier, literally. [More]
Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine. [More]
Researchers shed light on the dual action of aspirin

Researchers shed light on the dual action of aspirin

Hugely popular non-steroidal anti-inflammation drugs like aspirin, naproxen (marketed as Aleve) and ibuprofen (Advil, Motrin) all work by inhibiting or killing an enzyme called cyclooxygenase - a key catalyst in production of hormone-like lipid compounds called prostaglandins that are linked to a variety of ailments, from headaches and arthritis to menstrual cramps and wound sepsis. [More]
Acetyl fentanyl is more potent and dangerous than heroin

Acetyl fentanyl is more potent and dangerous than heroin

Emergency physicians should expect "an upswing in what on the surface appear to be heroin overdoses," but are actually overdoses tied to acetyl fentanyl, an opiate that is mixed into street drugs marketed as heroin. [More]
University of Kansas researcher earns grant to study role of dietary supplement in muscle growth

University of Kansas researcher earns grant to study role of dietary supplement in muscle growth

A University of Kansas professor has been chosen to take part in a grant project that will test the role of a dietary supplement in muscle growth for everyone from athletes to the elderly and has also been named educator of the year by the granting agency. [More]
Novartis and Gamida Cell sign Option and Investment Agreements

Novartis and Gamida Cell sign Option and Investment Agreements

​Elbit Imaging Ltd. announced today that Elbit Medical Technologies Ltd., a subsidiary of the Company in which it holds approximately 86% of the voting power, announced that on August 18, 2014, Gamida Cell Ltd., in which Elbit Medical holds approximately 30.8% of the voting power and a vast majority of Gamida Cell's shareholders (including Elbit Medical), signed Option and Investment Agreements with Novartis Pharma AG (Novartis). [More]
New research finds that early use of antibiotics can alter immunity later on

New research finds that early use of antibiotics can alter immunity later on

New University of British Columbia research found that receiving antibiotic treatments early in life can increase susceptibility to specific diseases later on. [More]
UC Santa Cruz cancer researcher receives $350,000 to develop novel drugs for breast cancer

UC Santa Cruz cancer researcher receives $350,000 to develop novel drugs for breast cancer

UC Santa Cruz cancer researcher Seth Rubin has received a $350,000 grant to fund his work toward the development of a new class of drugs for treating breast cancer. The grant is a Breast Cancer Research Program Breakthrough Award from the congressionally directed medical research programs of the U.S. Department of Defense. [More]
New research report provides overview of generic drug market in Japan

New research report provides overview of generic drug market in Japan

Research and Markets has announced the addition of the "The Overveiw of Japanese Generic Drug Market" report to their offering. [More]
Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway. [More]